EP4247344A1 - Procédé et dispositif pour produire un liquide contenant des liposomes et liquide produit - Google Patents

Procédé et dispositif pour produire un liquide contenant des liposomes et liquide produit

Info

Publication number
EP4247344A1
EP4247344A1 EP21819358.9A EP21819358A EP4247344A1 EP 4247344 A1 EP4247344 A1 EP 4247344A1 EP 21819358 A EP21819358 A EP 21819358A EP 4247344 A1 EP4247344 A1 EP 4247344A1
Authority
EP
European Patent Office
Prior art keywords
liquid
liposomes
mixer
particularly preferably
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21819358.9A
Other languages
German (de)
English (en)
Inventor
Regina BLEUL
Raphael THIERMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Forderung der Angewandten Forschung eV
Publication of EP4247344A1 publication Critical patent/EP4247344A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Definitions

  • a method and a device for the production of a liquid containing liposomes are provided.
  • the method is characterized in that a first liquid and a second liquid are fed into a micro-mixer and to the outlet of the micro-mixer by gas pressure from at least one source of gas, optionally additionally by at least one device for conveying liquid, with the total flow rate of the liquids is adjusted so that it is at least 10 mL/min at the outlet of the micromixer.
  • the method and the device make it possible to provide liquids containing liposomes with a narrow size distribution in a simple and reproducible manner on an industrial scale. Furthermore, a liquid containing liposomes with a narrow size distribution is provided and uses thereof are proposed. Liposomes are the most established nanocarrier systems in pharmaceutical use worldwide. Doxil® was the first "nanodrug" to be approved by the FDA in 1995.
  • nano-liposomes on an industrial scale is a multi-stage batch process.
  • the lipids mostly large, multilamellar liposomes (MLV) are hydrated.
  • MLV multilamellar liposomes
  • downsizing is carried out in order to obtain nanoliposomes with a diameter of ⁇ 200 nm.
  • high-pressure extrusion is carried out through a membrane that has corresponding nano-sized pores (example: production of Doxil®)
  • high-pressure homogenization is carried out (examples: production of AmbiSome® and for nano-liposomes used in cosmetics).
  • Extrusion must be performed at elevated temperatures because the MLV lipid bilayers must be flexible enough to allow for shape changes required to achieve size reduction. Multiple passes through the extrusion membrane are necessary to achieve the narrow size distribution required. This procedure is time-consuming. In addition, this procedure is limited to heat-resistant lipid raw materials and corresponding embedded or encapsulated substances. In addition, the extrusion process is associated with material loss on the membrane. Furthermore, clogging (clogging) of the membranes requires frequent membrane replacement and the loss of possibly valuable substances such as lipids and active ingredients, which jeopardizes the implementation of a production process for providing a sterile liquid with liposomes and makes it more expensive.
  • the polycarbonate membranes usually used also show batch fluctuations due to different properties such as pore size, pore uniformity and surface wetting, which leads to a lack of process reproducibility.
  • high-pressure homogenization often leads to broad size distributions, including the production of large percentages of very small liposomes.
  • the high-pressure homogenization must also be carried out at high temperatures.
  • a method for the rapid and simple large-scale production of a sterile liquid containing nanometer-sized liposomes There is also a need for formulation methods for thermolabile (sensitive) lipids and drugs.
  • next-generation drugs such as nucleic acid-based immunotherapeutics.
  • WO 2017/103268 A1 discloses a continuous method for producing nanoparticles. The method disclosed there is not suitable for the large-scale production of sterile liquids containing liposomes.
  • EP 1337322 B1 discloses a method for producing lipid vesicles. This method is not strictly microfluidic and is limited in the use of demanding API (e.g. ultrahydrophobic agents) in the preparation of the liposomes. Furthermore, the narrowness of the size distribution of the liposomes produced can still be improved.
  • demanding API e.g. ultrahydrophobic agents
  • WO 2014/172045 A1 discloses a method for the industrial production of sterile liposome solutions on a large scale.
  • the reproducibility is problematic because the production takes place via a platform in which an absolutely equal distribution of the various channels of the platform must be ensured, which is not easy.
  • a continuous method for producing a liquid containing liposomes comprising the steps of a) providing a first liquid in a first container, the first liquid containing or consisting of at least one lipid; b) providing a second liquid in a second container, the second liquid containing or consisting of water; c) directing the first liquid along a first fluid line into a first inlet of a micro-mixer and in flow to an outlet of the micro-mixer; d) directing the second liquid along a second fluid line into a second inlet of the micromixer and in a flow alongside the first liquid to the outlet of the micromixer; wherein the first liquid and the second liquid mix within the micro-mixer, so that a liquid containing liposomes emerges at the outlet of the micro-mixer;
  • liposomes is understood to mean liposomes, liposomes and lipid nanoparticles, which can optionally be loaded with a substance (for example an active ingredient), with “loaded” meaning that a cavity inside the lipid particles and/or or a membrane of the lipid particles (preferably both) contains or contain a substance (eg an active ingredient).
  • a substance for example an active ingredient
  • the liposomes (ie the liposomes, lipoplexes and/or lipid nanoparticles) have in particular a diameter in the range from 20 nm to ⁇ 200 nm or in the range from >200 nm to ⁇ 500 nm, preferably in the range from 40 nm to 150 nm or in the range from 250 nm to 400 nm, particularly preferably in the range from 60 nm to 120 nm or in the range from 300 nm to 350 nm.
  • the diameter can be determined by dynamic light scattering and/or cryogenic Transmission electron microscopy, preferably via a measurement with cryogenic transmission electron microscopy, determined or be determined.
  • micro-mixer is preferably understood to mean all mixers whose mixing principle is based on the mixing principle of a micro-mixer, including those that are so large (scaled) that their fluid channels have larger dimensions (i.e. cross-sections) than in the micrometer range (range from 1 pm to 1000 pm).
  • the method according to the invention it is possible to provide liquids which contain liposomes with a narrow size distribution in a simple and reproducible manner on an industrial scale.
  • the method is also suitable for ensuring that sterile liquids containing liposomes can be provided since the liquid delivery takes place by gas pressure from at least one source of gas (optionally additionally by at least one device for liquid delivery).
  • the optional device for conveying liquid is arranged downstream of the at least one source of gas and its liquid-contacting surfaces can be ensured to be sterile. Since the components used in the process (e.g. the fluid lines and the micromixer) are sealed off from the outside, it can also be ensured that the liquids do not come into contact with microorganisms and/or viruses.
  • a micro-mixer enables a high level of control over the structure formation of the liposomes, ie excellent size control is possible and very narrow size distributions can be achieved.
  • Another advantage is that the method can be scaled up without having to be readjusted, ie without having to ensure, for example, an equal distribution of the streams during the "numbering-up" of the individual micromixers, which is often necessary for micromixers ("external numbering-up") and/or without having to change the mixer type.
  • a larger mixer of the same type (“scalable micromixer") can be used (e.g.
  • Scalable micromixers which can be used according to the invention as mixers or micromixers, are particularly characterized in that they do not require any additional distribution lines and collection lines in the event of scaling et al., Chemical Engineering Journal, Vol. 334, pp. 1996-2003), StarLam-like micromixers (e.g. as disclosed in DE 199 27 556 C2) and/or cyclone mixers (e.g. as disclosed in EP 1 390 131 B1) .
  • the method can be characterized in that all surfaces with which the first and second liquid come into contact on the way to the outlet of the micromixer are sterile. Furthermore, it is preferred that all of these surfaces are closed off in a fluid-tight manner to the outside, preferably form a closed system.
  • the advantage here is that the conditions for the micromixer and the fluid delivery devices (eg the gas pressure from at least one gas source, optionally the additional device for liquid delivery) can be set very precisely, which is advantageous for achieving desired PDI values and others quality criteria.
  • the liquids used do not come into contact with microorganisms and/or viruses. Apart from that, it is preferred that all of these surfaces have no areas where residues can collect.
  • none of these surfaces contain or consist of glass.
  • all of the fluids used in the method eg the first and second sterile liquids and the gas from the gas source
  • the same can apply to all components used in the process (e.g. micromixer, conveyor devices and containers), at least for their surfaces that come into contact with the fluids used in the process.
  • the method may be characterized in that the at least one source of gas includes or consists of a gas container.
  • the at least one source of gas may have a first fluidic connection to the first container and a second fluidic connection to the second container.
  • the at least one source of gas can contain a gas that does not contain oxygen, the gas preferably containing or consisting of a gas selected from the group consisting of nitrogen, noble gas and mixtures thereof.
  • the gas pressure of the source of gas provides a delivery pressure, optionally together with a liquid delivery device.
  • the total flow rate can be set here via a constant gas pressure from the source of gas, optionally also via the device for conveying liquid.
  • the gas pressure alone is preferably in the range of ⁇ 12 bar, more preferably ⁇ 8 bar, particularly preferably ⁇ 6 bar, very particularly preferably greater than 1 to 6 bar, in particular 1.5 to 5 bar.
  • delivery pressures of up to 50 bar can be achieved.
  • the total flow rate can then be kept constant via at least one, preferably at least one first and at least one second flow regulator, with the at least one first flow regulator particularly preferably being arranged on the first fluidic connection and the at least one second flow regulator being arranged on the second fluidic connection.
  • the at least one flow regulator serves to convert the original delivery pressure into a constant flow rate.
  • the gas source (then optionally the device for conveying liquid) and then the at least one flow regulator are arranged in the direction of flow.
  • the pressure loss in the mixing chamber of the mixer is preferably low, preferably in the range of ⁇ 6 bar, in particular in the range from 1.5 to 5 bar.
  • the total flow rate can be adjusted so that at the outlet of the micromixer it is ⁇ 80 mL/min, preferably ⁇ 320 mL/min, particularly preferably ⁇ 1280 ml/min, very particularly preferably ⁇ 2800 ml/min, in particular ⁇ 5120 mL/min.
  • the total flow rate can be set so that the mixer at the outlet of the micro-mixer per cross-sectional area of the outlet of the micro- ⁇ 20 ml / (min-mm 2 ), preferably ⁇ 100 ml / (min-mm 2 ), particularly preferably ⁇ 200 ml/(min-mm 2 ), very particularly preferably ⁇ 400 ml/(min-mm 2 ), optionally ⁇ 1000 ml/(min-mm 2 ), in particular from 100 to 400 ml/(min-mm 2 ), amounts to.
  • the total flow rate can be set such that the ratio of the flow rate of the second liquid to the flow rate of the first liquid is ⁇ 100:1, preferably ⁇ 20:1, particularly preferably ⁇ 16:1, very particularly preferably ⁇ 8:1 more preferably ⁇ 7:1, more preferably ⁇ 6:1, very much preferably ⁇ 5:1, in particular ⁇ 4:1.
  • the total flow rate can have a flow rate variation of less than 1% of the total flow rate, preferably less than 0.1% of the total flow rate.
  • the advantage here is that very low PDI values are achieved.
  • the overall flow rate can be adjusted in such a way that the flow has a Reynolds number in the range from >80 to ⁇ 1200, preferably >120 to ⁇ 1000.
  • the method can be characterized in that the micromixer has one or more mixing structures which extend obliquely or transversely to the direction of flow and are preferably suitable for deflecting the first liquid and/or second liquid in a direction obliquely or transversely to the direction of flow .
  • the micromixer particularly preferably all of the components used in the process, can contain or consist of stainless steel.
  • the advantage here is that the micro-mixer or all components used in the process can be sterilized simply by exposure to heat and cleaning validation can be established. Consequently, the micro-mixer does not have to be a single-use product whose reproducible mixing performance must be constantly checked and validated.
  • the other components used in the process ie to the entire device for carrying out the process if it contains or consists of stainless steel.
  • micromixer can be autoclavable.
  • the micromixer can be dismantled into at least two parts for cleaning fluid channels of the micromixer.
  • the micro-mixer can be a “split-recombine” micro-mixer, with the micro-mixer preferably being a “ramp-up/ramp-down” micro-mixer, particularly preferably a “caterpillar”-type micro-mixer (see, for example, Hermann et al. , Chemical Engineering Journal, Vol. 334, pp. 1996-2003.
  • Caterpillar-type micromixers have been found to have several advantages. First, they have a continuous channel. This is in contrast to many other "split-recombine” micromixers, in which the main channel is split up into, for example, section-by-section, fluidically separate channels, which then subsequently reunite.
  • the inclined surfaces are preferably inclined by less than 70°, particularly preferably less than 55° and very particularly preferably by less than 45° relative to the main flow direction (ie relative to a flow direction parallel to the walls of the fluid channels of the micromixer). Consequently, the liquid containing the liposomes is produced more gently, ie there is less degradation of the starting materials and the products.
  • this micromixer is very easily scalable, for example by increasing the cross-sectional area of the mixing channel perpendicular to the main flow direction while retaining the repeating basic structure typical of the caterpillar-like micromixer. With increasing magnification, the mixing performance if necessary, be adjusted by increasing the number of repeating basic structures.
  • the micro-mixer can also be a "split in micro-lamellae and combine in multilaminated stream" micro-mixer, particularly preferably a "StarLam” micro-mixer (see e.g. DE 199 27 556 C2 and Werner, B. et al., Chemical Engineering Technology, 2005, Vol. 28, p. 401ff) This has the advantage that it can also be made of stainless steel, is easy to assemble and disassemble and also shows simple scalability.
  • the micro-mixer in particular the "caterpillar" micro-mixer, following the mixing chamber has an essentially non-narrowing and/or an essentially straight outlet.
  • the advantage here is that there is no abrupt change in direction and/or narrowing of the cross-section of the fluid flow comes, there are no dead spaces and only a lower pressure loss and low shear forces act.
  • the method can be characterized in that the first liquid contains lipids in a total concentration of > 30 g/L, preferably > 50 g/L, particularly preferably > 80 g/L, very particularly preferably > 150 g/L, in particular 160 g/L to 400 g/L (optionally 210 g/L to 290 g/L).
  • the first liquid can contain at least one phospholipid, preferably at least one zwitterionic or anionic phospholipid, the phospholipid preferably being selected from the group consisting of phosphatidylcholine, DSPC, DOPE, DOPC, DSPE, HSPC and mixtures thereof, the concentration of the at least one phospholipid, or mixtures thereof, preferably >20 g/L, preferably >40 g/L, particularly preferably >80 g/L, very particularly preferably >160 g/L, in particular 210 g/L to 400 g /L, is.
  • the first liquid can contain phospholipids with saturated fatty acid residues and/or unsaturated fatty acid residues, such as DSPC (saturated) and DOPC (unsaturated), or mixtures thereof.
  • the first liquid can contain at least one PEGylated lipid, preferably DSPE-PEG2000 and/or DMG-PEG2000, the concentration of the PEGylated lipid preferably being in the range from 15 to 40 mol %, in particular preferably in the range of 31 to 35% by moles, based on the molar fraction of at least one phospholipid in the first liquid.
  • the first liquid can contain at least one lipid, preferably at least one cationic lipid (e.g. a pH-dependent cationically charged lipid).
  • a pH-dependent cationically charged lipid e.g. a pH-dependent cationically charged lipid.
  • the first liquid may contain at least one lipidoid, the concentration of the lipid being preferably in the range from 200 to 1000 mol%, particularly preferably in the range from 300 to 800 mol%, in relation to the molar proportion of at least one lipid is in the first liquid.
  • lipidoid is understood to mean lipid-like substances which result from the reaction of acrylamides or acrylic acid esters with secondary or primary amines (i.e. are produced).
  • the pH-dependent cationic charge is preferably achieved by means of a primary, secondary or tertiary amino group
  • at least one lipidoid is meant, which is selected from the group of lipidoids mentioned in the publication by Acinc, A. et al., Nature Biotechnology (2008), vol are.
  • the first liquid may contain cholesterol.
  • the first liquid can be characterized in that it contains no nonionic, cationic, anionic and/or amphoteric surfactant, preferably contains no surfactant (at all).
  • the first liquid may contain at least one organic solvent or no organic solvent.
  • the organic solvent is preferably an organic, water-miscible solvent, particularly preferably a solvent selected from the group consisting of alcohols, particularly preferably ethanol, 1-propanol, 2-propanol, and/or methanol, Acetone, tetrahydrofuran, dioxane, acetonitrile, dimethyl sulfoxide, especially ethanol.
  • the first liquid is degassed. This prevents bubble formation during assembly of the liposomes.
  • the method can be characterized in that the second liquid contains a buffer substance, preferably a buffer substance selected from the group consisting of acetate, ammonium, citrate and combinations thereof, particularly preferably calcium acetate and/or ammonium sulfate.
  • concentration of the buffer substance is preferably in the range from 5 mM to 300 mM, particularly preferably in the range from 8 mM to 250 mM. The advantage of these concentrations is that the formation of a gradient is improved.
  • the second liquid is degassed. This prevents bubble formation during assembly of the liposomes.
  • the method can be characterized in that the liposomes of the liquid are loaded with at least one active substance, loading preferably taking place in the first micromixer, in a further mixer downstream of the first micromixer, after the liposomes have been assembled and/or after the liposomes are purified.
  • the active substance can be at least one organic active substance, preferably an active substance for treating a disease, particularly preferably a molecule selected from the group consisting of vitamin, protein, peptide, lipid, DNA, RNA, organic molecule with a mass ⁇ 500 Since and mixtures thereof, in particular contain or consist of a substance selected from the group consisting of ultrahydrophobic substance, siRNA and combinations thereof. Here the encapsulation is more demanding Active substances (e.g. ultrahydrophobic substances and/or siRNA) are possible which could not be encapsulated in other processes.
  • the active substance can contain or consist of at least one inorganic active substance, preferably a substance selected from the group consisting of magnetic substance, paramagnetic substance and mixtures thereof, particularly preferably iron oxide, manganese oxide and mixtures thereof.
  • the at least one active substance is preferably contained in the first liquid, in the second liquid and/or in another liquid (downstream of the micromixer).
  • the concentration of the at least one organic active substance and/or at least one inorganic active substance can be ⁇ 1% by weight, preferably 5 to 80% by weight, particularly preferably 10 to 60% by weight, in particular 15 to 30% by weight %, in relation to the total weight of the lipids (or the components of the liposomes except water).
  • the temperature can be from >10°C to ⁇ 70°C, preferably from 15 to 40°C , particularly preferably 22 to 30 ° C, in particular 23 ° C to 25 ° C, are heated. If necessary, the temperature can be adjusted to a temperature in the range from >0°C to ⁇ 10°C.
  • substances e.g. active ingredients
  • liposomes can be provided which have these temperature-sensitive substances.
  • the method can be characterized in that the liposomes of the liquid which emerge at the outlet of the micromixer are unilamellar liposomes, multilamellar liposomes or mixtures thereof.
  • the process can be designed in such a way that the liposomes of the liquid, which emerge at the outlet of the micromixer, have a diameter in the range from 20 nm to ⁇ 200 nm or in the range from >200 nm to ⁇ 500 nm, preferably in the range from 40 nm to 150 nm or in the range from 250 nm to 400 nm, particularly preferably in the range from 60 nm to 120 nm or in the range from 300 nm to 350 nm.
  • the diameter can be dynamic Light scattering and/or cryogenic transmission electron microscopy, preferably via a measurement using cryogenic transmission electron microscopy.
  • the process can be designed in such a way that the liposomes of the liquid that emerge at the outlet of the micromixer are more than 50%, more than 70%, or more than 90%, based on the total number of all liposomes in the liquid.
  • the method can be designed in such a way that the liposomes of the liquid that emerge at the outlet of the micromixer are more than 50%, more than 70% or more than 90%, based on the total number of all liposomes in the liquid, multilamellar liposomes and the liposomes have a PDI value in the range of ⁇ 0.500, preferably in the range of ⁇ 0.300, with regard to their size distribution.
  • the PDI can preferably be determined by means of dynamic light scattering according to the standard DIN ISO 22412:2018-09 or is determined in this way.
  • the method can be characterized in that the liquid is purified in a further step after step c), the purification being carried out preferably continuously after step c), particularly before ultrafiltration, gel filtration and/or evaporation - involves performing an ultrafiltration to enrich the liposomes.
  • the purification can include removing substances that are present alongside the liposomes, preferably removing buffer substances and/or organic solvents.
  • the purification can include exchanging substances that are present alongside the liposomes for a sterile, osmolar sugar solution, preferably for a sterile, osmolar glucose solution or sucrose solution.
  • the sterile, osmolar sugar solution particularly preferably has 4 to 15% by weight of sugar, in particular 4 to 6% by weight of glucose in the case of a glucose solution and/or 9 to 11% by weight of sucrose in the case of a sucrose solution.
  • the purification can Sterilization of the solution containing liposomes preferably comprises sterile filtration through a membrane with a pore diameter (cut-off) of 0.2 ⁇ m.
  • the method can further comprise the following steps i) conducting the liquid containing liposomes at the outlet of the micro-mixer along a third fluid line, optionally a dwell loop, into a first inlet of a further mixer and in a flow to an outlet of the further mixer; and ii) passing a further liquid along a fourth fluid line into a second inlet of the further mixer and in a stream alongside the liquid containing liposomes to the outlet of the further mixer.
  • the liquid containing liposomes mixes with the further liquid within the further mixer, so that a changed liquid containing liposomes emerges at the outlet of the further mixer.
  • the proportion of the solvent is preferably reduced and a further dilution is carried out, preferably a dilution to less than half, preferably less than a quarter, of the original concentration of the liposomes in the liquid.
  • the liposomes contained become more dimensionally stable.
  • other parameters, such as the pH can also be adjusted by the admixture, with the pH preferably being lowered or neutralized.
  • the liposomes can also be loaded with at least one active substance in this step.
  • the liquid containing liposomes and the further liquid can be conveyed into the further mixer by gas pressure from at least one source of gas, optionally also by at least one device for liquid delivery, with the total flow rate of the liquids being adjusted in such a way that they at the outlet of the further mixer is more than 10 mL/min, preferably at least 20 mL/min.
  • the further mixer is preferably a micromixer, preferably a static micromixer, particularly preferably a “split-recombine” micromixer, very particularly preferably a “caterpillar”-type micromixer. Alternatively, a so-called “StarLam" micro-mixer can also be used. Both mixers can be easily adaptable in relation to the required flow rate.
  • the liposomes of the liquid can be loaded with at least one active substance in the first micromixer, in the further mixer, after the liposomes have been assembled and/or after the liposomes have been purified.
  • a device for producing a liquid containing liposomes containing a) a first container containing a first liquid, the first liquid containing or consisting of at least one lipid; b) a second container containing a second liquid, the second liquid containing or consisting of water; c) a micromixer which has a first input, a second input and an output, the first container being connected to the first input of the micromixer via a first fluid line and the second container being connected to the second input of the micromixer via a second fluid line is connected, wherein the micro-mixer is configured to allow the first liquid and the second liquid to flow in a stream within the micro-mixer to the outlet of the micro-mixer and to mix them within the micro-mixer, with a liquid containing liposomes emerging at the outlet of the micro-mixer ; d) at least one source of gas, optionally also at least one device for conveying liquid; and e) a control unit; characterized in that the at least
  • the device can be characterized in that all surfaces of the device with which the first and second liquid can come into contact on the way to the outlet of the micromixer are sterile. Further all of these surfaces of the device can be closed off in a fluid-tight manner to the outside, preferably form a closed system.
  • the advantage here is that the conditions for the micromixer and the fluid delivery devices (eg the gas pressure from at least one gas source, optionally the additional device for liquid delivery) can be set very precisely, which is advantageous for achieving desired PDI values and other quality criteria.
  • the liquids used do not come into contact with microorganisms and/or viruses. That being said, all of these surfaces can be said to have no areas where debris can collect.
  • none of these surfaces contain or consist of glass.
  • Each of these features contributes to ensuring that the device can be used to continuously produce a sterile liquid containing liposomes, ie the liquid cannot be contaminated during its production.
  • all of the fluids present in the device eg the first and second sterile liquids and the gas from the gas source
  • the device can be characterized in that the device and/or the control unit of the device is/are configured to carry out the method according to the invention.
  • the device can have features that are mentioned above in connection with the method according to the invention and/or the control unit of the device can be configured to carry out steps that are mentioned above in connection with the method according to the invention.
  • a liquid containing liposomes which is characterized in that i) more than 50%, more than 70% or more than 90% of all liposomes in the liquid are unilamellar liposomes and the liposomes with regard to their size distribution a PDI value in the range of ⁇ 0.200, preferably in the range of ⁇ 0.150, particularly preferably in the range of ⁇ 0.100 particularly preferably in the range of ⁇ 0.090, in particular in the range of ⁇ 0.075; or ii) more than 50%, more than 70% or more than 90% of all liposomes in the liquid are multilamellar liposomes and the liposomes have a PDI value in the range of ⁇ 0.500, preferably in the range of ⁇ , with regard to their size distribution have 0.300; where the PDI is preferably determined by means of dynamic light scattering according to the standard DIN ISO 22412:2018-09.
  • a liquid that contains liposomes with a small PDI it can be better ensured that the liquid does not contain a dangerous proportion of liposomes that are too large, which are considered a risk factor for promoting the formation of embolisms.
  • a smaller PDI can therefore also offer a higher security aspect.
  • the stability of the liposomes is more uniform the smaller their PDI is, which allows more precise statements to be made about the storage capacity, transport stability and handling of the liposomes.
  • a smaller PDI of the liposomes means that when the liposomes are loaded with active substance, the active substance content per liposome is more uniform, which enables more precise active substance dosing.
  • the liquid can be produced by the method according to the invention.
  • the liquid containing liposomes provided is sterile.
  • the liquid is proposed for use in medicine, preferably for use in a method for the therapeutic treatment of the human or animal body, particularly preferably i) for the application of an active substance, particularly preferably for the topical application of an active substance; and/or ii) for targeting of an active substance; and/or iii) for the release of an active ingredient; in a method for the surgical or therapeutic treatment of the human or animal body, the active ingredient preferably being selected from the group consisting of vaccine, cytostatic agent, corticoid and combinations thereof (doxorubine and/or dexamethasone) and the treatment being in particular is the treatment of cancer, an inflammatory disease, a disease of the immune system and/or a neurodegenerative disease.
  • the active substance can optionally be at least one of the organic active substances mentioned above (in connection with the method according to the invention).
  • the liquid is proposed for use in a diagnostic method, preferably in a diagnostic method that is carried out on the human or animal body, in particular in a diagnostic method in which the liposomes contain a biomarker.
  • the at least one organic active substance and/or the at least one inorganic active substance can be one of the active substances mentioned above (in connection with the method according to the invention).
  • FIG. 1 shows a device according to the invention, which has a single micro-mixer 3 .
  • the first liquid, which is in a first container 1, and the second liquid, which is in a second container 2 are supplied by gas pressure, coming from two sources 9, 9' of gas, via a first fluid line 7 in introduced into a second inlet 5 of the micromixer 3 via a second fluid line 8 and transported to the outlet 6 of the micromixer.
  • a flow regulator 11, 11' ensures that the liquid flow in these fluid lines 7, 8 is kept at a desired value.
  • the outlet 6 of the first micro-mixer is fluidically connected to a reservoir 10 so that the liquid containing liposomes emerging from the first micro-mixer 3 is conducted into the reservoir 10 .
  • FIG. 2 shows a device according to the invention, which has a first micromixer 3 and a second micromixer 12 .
  • the first liquid, which is in a first container 1, and the second liquid, which is in a second container 2 are introduced by gas pressure, originating from two sources 9, 9' of gas, via a first fluid line 7 into the first Input 4 or via a second fluid line 8 introduced into a second input 5 of the micro-mixer 3 and transported to the output 6 of the micro-mixer.
  • a liquid containing liposomes emerges at the outlet of the micromixer 3 and is conducted via a third fluid line 20 into a first inlet 14 of a further mixer 12 (here: a further micromixer).
  • FIG. 3 shows a device according to the invention, which is constructed like the device shown in FIG. here: a pump) is supported in order to achieve the necessary delivery pressure.
  • the device 17 for conveying liquids also has the property of a flow regulator and ensures that the respective liquid flow in the first fluid line 7, the second fluid line 8 and the fourth fluid line 21 is kept at a desired value.
  • FIG 4 shows a device according to the invention, which is constructed essentially like the device shown in Figure 3, the device 17 for conveying liquids being a magnetic gear pump and downstream of the outlet 15 of the second micro-mixer 12 a 3-way valve 19 is arranged.
  • the liquid containing liposomes emerging from the second micromixer 12 can be conducted via the 3-way valve 19 either into a storage container 10 or via an ultrafiltration module 18 into another storage container 10′, 10′′.
  • the device contains a micromixer and a second micromixer connected after a short dwell loop at the outlet of the first micromixer, for example to achieve more asymmetric flow conditions or to achieve dilution before purification by diafiltration to further reduce solvent content.
  • the micromixer(s) and residence loop can be temperature-controlled if required.
  • a diafiltration module membrane stack
  • membrane stack can also be connected, which can be operated directly in series or as a separate module in the circuit.
  • the micromixer is preferably a "split-and-recombine” micromixer, particularly preferably a "Caterpillar” micromixer (continuous mixing channel with several mixing stages).
  • the mixing channel of this micro-mixer has a diameter in the micrometer to millimeter range. "Upscaling" is of course possible here. For example, the same product quality can be achieved when using a bead 600 with four times the flow rate and with a bead 1200 with 16 times the flow rate compared to R-300.
  • Bead 600: 8 - 320 ml/min 22.22 ml/(min *mm 2 ) - 888.88 ml/(min*mm 2 )
  • Bead 1200: 32 - 1280 ml/min 22.22 ml/(min*mm 2 ) - 888.88 ml/(min*mm 2 )
  • the micro-mixer and/or the second micro-mixer can also be a so-called StarLam micro-mixer.
  • the StarLam micro-mixer is also scalable and can be operated, for example, as StarLam 30, 300 and 3000 with flow rates from 12 l/h to 8000 l/h.
  • the two liquids are mixed at room temperature with an R300 bead.
  • This mixer works almost optimally under these flow conditions: Sufficient mixing, low pressure drop, straight outlet, solid process control, low risk of blockage, comparatively easy cleaning, open in two halves for cleaning and drying. This is then filled without purification. The liquid is stored in the refrigerator overnight.
  • the cationic lipidoid was combined with cholesterol, DSPC and DMG-PEG2000 and each dissolved in 90% ethanol (10% 10 mM citrate buffer, pH 3) in the molar ratio of the cationic lipid, with the molar ratios of DSPC: cholesterol: DMG-PEG2000 were 50:10:38.5:1.5.
  • si-RNA polynucleotide (30 pM) was dissolved in 10 mM citrate buffer, pH 3.0, to prepare a polynucleotide solution.
  • the polynucleotide solution and the lipid solution were mixed in a first micromixer (total flow rate 10 ml/min).
  • the mixed product was mixed in a second micro-mixer (total flow rate 20 ml/min) mixed with PBS buffer.
  • the freshly prepared lipid nanoparticles were dialyzed against PBS buffer to remove ethanol, exchange buffer, and unbound siRNAs.
  • Device for conveying liquid e.g. magnetic gear pump

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

L'invention concerne un procédé et un dispositif pour produire un liquide contenant des liposomes. Le procédé est caractérisé en ce que l'acheminement d'un premier liquide et d'un second liquide vers un micromélangeur et jusqu'à la sortie du micromélangeur est réalisé sous l'effet d'une pression de gaz provenant d'au moins une source de gaz, éventuellement également par l'intermédiaire d'au moins un dispositif de refoulement de liquide, le débit total des liquides étant réglé de telle sorte qu'il s'élève à au moins 10 mL/min à la sortie du micromélangeur. Le procédé et le dispositif permettent d'obtenir, de manière simple et reproductible à l'échelle industrielle, des liquides qui contiennent des liposomes ayant une distribution granulométrique étroite. L'invention concerne en outre un liquide contenant des liposomes ayant une distribution granulométrique étroite et des utilisations de ce liquide.
EP21819358.9A 2020-11-19 2021-11-19 Procédé et dispositif pour produire un liquide contenant des liposomes et liquide produit Pending EP4247344A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102020214601.2A DE102020214601A1 (de) 2020-11-19 2020-11-19 Verfahren und Vorrichtung zur Herstellung einer Flüssigkeit enthaltend Liposomen und hergestellte Flüssigkeit
PCT/EP2021/082320 WO2022106627A1 (fr) 2020-11-19 2021-11-19 Procédé et dispositif pour produire un liquide contenant des liposomes et liquide produit

Publications (1)

Publication Number Publication Date
EP4247344A1 true EP4247344A1 (fr) 2023-09-27

Family

ID=78821216

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21819358.9A Pending EP4247344A1 (fr) 2020-11-19 2021-11-19 Procédé et dispositif pour produire un liquide contenant des liposomes et liquide produit

Country Status (6)

Country Link
US (1) US20240033220A1 (fr)
EP (1) EP4247344A1 (fr)
CN (1) CN116635078A (fr)
DE (1) DE102020214601A1 (fr)
IL (1) IL302987A (fr)
WO (1) WO2022106627A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19927556C2 (de) 1999-06-16 2003-05-08 Inst Mikrotechnik Mainz Gmbh Statischer Mikromischer und Verfahren zum statischen Mischen zweier oder mehrerer Edukte
EP1203614A1 (fr) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Procédé et dispositif pour la préparation de vésicules de lipides
DE10123093A1 (de) 2001-05-07 2002-11-21 Inst Mikrotechnik Mainz Gmbh Verfahren und statischer Mikrovermischer zum Mischen mindestens zweier Fluide
RU2573409C2 (ru) * 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
US9693958B2 (en) * 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
WO2014172045A1 (fr) 2013-03-15 2014-10-23 The University Of British Columbia Nanoparticules lipidiques pour la transfection et procédés associés
DE102015226018A1 (de) * 2015-12-18 2017-06-22 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Kontinuierliches Verfahren zur Herstellung von vesikulären oder scheibenförmigen, supramolekularen Nanopartikeln, und Verwendungen hiervon
EP3915544A1 (fr) * 2020-05-25 2021-12-01 Leon-Nanodrugs GmbH Procédé de production d'une dispersion de liposomes

Also Published As

Publication number Publication date
US20240033220A1 (en) 2024-02-01
CN116635078A (zh) 2023-08-22
DE102020214601A1 (de) 2022-05-19
WO2022106627A1 (fr) 2022-05-27
IL302987A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
EP1337322B1 (fr) Procede et dispositif pour produire des vesicules lipidiques
DE60132094T2 (de) Verfahren zur Herstellung von gereinigten Partikeln
EP1838286B1 (fr) Production de nanoparticules a base de lipides au moyen d'une centrifugeuse asymetrique double
EP1289642B2 (fr) Nanocapsules a enveloppe de polyelectrolyte
DE69837339T2 (de) Veränderung der Wirkstoffladung in multivesikulären Liposomen
EP0032578A1 (fr) Procédé et installation de dialyse pour la préparation de vésicules à deux couches et leur utilisation
EP1180062A1 (fr) Procede de production de microparticules et nanoparticules morphologiquement homogenes a l'aide d'un micromelangeur
JPH0131414B2 (fr)
WO2002094222A2 (fr) Procede de production de nanodispersions
WO1994008626A1 (fr) Procede et dispositif de preparation de systemes disperses liquides
WO2020035162A1 (fr) Procédé d'encapsulation de substances actives dans des liposomes
DE3815473C2 (fr)
EP4247344A1 (fr) Procédé et dispositif pour produire un liquide contenant des liposomes et liquide produit
EP0488142B1 (fr) Procédé pour encapsuler des principes actifs lipophiles solides ou liquides dans des liposomes phospholipidiques ainsi que des médicaments contenant ces liposomes
EP2374535A1 (fr) Procédé et dispositifs de formation de vésicule, notamment en utilisant des copolymères en bloc
EP4059491A1 (fr) Dispositif et procédé de production de nanoporteuses et/ou de nanoformulations
WO2017103268A1 (fr) Procédé continu de production de nanoparticules supramoléculaires vésiculaires ou discoïdes ainsi que leur utilisation.
KR20190134582A (ko) 혼합 세라마이드를 포함하는 화장료 조성물 제조방법 및 상기 방법에 의해 제조한 화장료 조성물
DE4328331A1 (de) Kontinuierliches Hochdruckextrusionsverfahren zur Herstellung von Liposomen und Emulsionen
DE102022115653A1 (de) Verfahren zur Medikament- und Impfstoffherstellung
EP3836901A1 (fr) Procédé pour encapsuler des principes actifs dans des liposomes
DE102006054192A1 (de) Effizientes Verfahren zur Beladung von amphoteren Liposomen mit Nukleinsäure-Wirkstoffen
WO2023148303A1 (fr) Procédé de production de médicaments et de vaccins

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)